A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities

Antimicrobial Agents and Chemotherapy - Tập 42 Số 11 - Trang 2841-2847 - 1998
Alexander A. Firsov1, Sergey N. Vostrov1, Alexander Alekseevich Shevchenko1, Yury A. Portnoy1, Stephen H. Zinner2
1Department of Pharmacokinetics, Centre of Science & Technology LekBioTech, Moscow 117246, Russia,1 and
2Division of Infectious Diseases, Roger Williams Medical Center, Rhode Island Hospital, Brown University, Providence, Rhode Island2

Tóm tắt

ABSTRACT Time-kill studies, even those performed with in vitro dynamic models, often do not provide definitive comparisons of different antimicrobial agents. Also, they do not allow determinations of equiefficient doses or predictions of area under the concentration-time curve (AUC)/MIC breakpoints that might be related to antimicrobial effects (AMEs). In the present study, a wide range of single doses of trovafloxacin (TR) and twice-daily doses of ciprofloxacin (CI) were mimicked in an in vitro dynamic model. The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (μg · h/ml)/(μg/ml), respectively]. The observation periods were designed to include complete bacterial regrowth, and the AME was expressed by its intensity (the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill and regrowth curves up to the point where viable counts of regrowing bacteria equal those achieved in the absence of drug [ I E ]). In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively. Linear relationships between I E and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MIC TR ] = 0.25 μg/ml; MIC of CI [MIC CI ] = 0.12 μg/ml), Pseudomonas aeruginosa (MIC TR = 0.3 μg/ml; MIC CI = 0.15 μg/ml), and Klebsiella pneumoniae (MIC TR = 0.25 μg/ml; MIC CI = 0.12 μg/ml). The slopes and intercepts of these relationships differed for TR and CI, and the I E -log AUC/MIC plots were not superimposed, although they were similar for all bacteria with a given antibiotic. By using the relationships between I E and log AUC/MIC, TR was more efficient than CI. The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (μg · h/ml)/(μg/ml)] was approximately twofold lower than that for CI. Based on the I E -log AUC/MIC relationships, the respective dose ( D )-response relationships were reconstructed. Like the I E -log AUC/MIC relationships, the I E -log D plots showed TR to be more efficient than CI. Single doses of TR that are as efficient as two 500-mg doses of CI (500 mg given every 12 h) were similar for the three strains (199, 226, and 203 mg). This study suggests that in vitro evaluation of the relationships between I E and AUC/MIC or D might be a reliable basis for comparing different fluoroquinolones and that the results of such comparative studies may be highly dependent on their experimental design and datum quantitation.

Từ khóa


Tài liệu tham khảo

10.1093/jac/40.5.639

Bergan T. Thorsteinsson S. B. Pharmacokinetics and bioavailability of ciprofloxacin Proceedings of the 1st International Ciprofloxacin Workshop Current clinical practice series 34. Neu H. C. Weuta H. 1986 111 121 Elsevier Science Publishers B.V. (Excerpta Medica) Amsterdam The Netherlands

Blaser J. Zinner S. H. In vitro models for the study of antibiotic activities. Prog. Drug Res. 31 1987 349 381

Dalhoff A. 1995. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae . Drugs 49 (Suppl. 2):194–196.

Dalhoff A. 1995. Pharmacodynamics of quinolones. Drugs 49 (Suppl. 2):197–199.

Felmingham D. M. J. Robbins K. Ingley I. Mathias H. Bhogal A. Leakey G. L. Ridgway and R. N. Grüneberg. 1997. In-vitro activity of trovafloxacin a new fluoroquinolone against recent clinical isolates. J. Antimicrob. Chemother. 39 (Suppl. B):43–49.

Firsov A. A. In vitro simulated pharmacokinetic profiles: forecasting antibiotic optimal dosage. Eur. J. Drug Metab. Pharmacokinet. Special Issue 3 1991 406 409

Firsov A. A. 1993. Critical reappraisal of modern approaches to search determinants of efficacy of antimicrobials. Eur. Bull. Drug Res. 2 (Suppl. 1):33–38.

10.1128/AAC.34.7.1312

Firsov A. A. Nazarov A. D. Chernykh V. M. Pharmacokinetic approaches to rational antibiotic therapy Advances in science and engineering 17 1989 1 228 VINITI Publishers Moscow, Russia (In Russian.)

10.1128/AAC.40.3.734

10.1128/AAC.42.3.659

10.1128/AAC.41.6.1281

10.1128/AAC.37.5.1073

10.1128/AAC.39.10.2210

Graham D. R. Klein T. Torres A. Niedermann M. the Trovan Nosocomial Pneumonia Study Group A double blind randomized multicenter study of nosocomial pneumonia (NOS) comparing trovafloxacin with ciprofloxacin ± clindamycin/metronidazole abstr. LM-74 Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 378 American Society for Microbiology Washington D.C

10.1128/AAC.27.3.375

10.1128/AAC.38.12.2702

10.1093/jac/37.4.703

10.1128/AAC.40.3.627

Murakawa T. In vitro/in vivo kinetic models for evaluating efficacy of antimicrobial agents Pharmacokinetics of antimicrobial agents: principles methods applications part IV. Pharmacokinetics and therapeutic efficacy section IV-1. Kuemmerle H.-P. Murakawa T. Nightingale C. H. 1993 165 177 Ecomed Verlags GmbH & Co. KG Landsberg/Lech Germany

Niederman M. Traub S. Ellison W. T. Hopkins D. W. the Trovan Pneumonia Study Group A double blind randomized multicenter global study in hospitalized community acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone + erythromycin abstr. LM-72 Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 377 American Society for Microbiology Washington D.C

Nightingale C. H. Pharmacokinetic considerations in quinolone therapy. Pharmacotherapy 13 2 Pt. 2 1993 34S 38S

Schentag J. J. Nix D. E. Adelman M. H. Mathematical examination of dual individualization principles. Relationships between AUC above MIC and area under the inhibitory curve (AUC/MIC) for cefmenoxime, ciprofloxacin, and tobramycin. DICP-Ann. Pharmacother. 25 1991 1050 1057

Schentag J. J. Nix D. E. Forrest A. Pharmacodynamics of the fluoroquinolones Quinolone antimicrobial agents 2nd ed. Hooper D. C. Wolfson J. S. 1993 259 271 American Society for Microbiology Washington D.C

Sullivan J. Gezon J. Williams Hopkins D. the Trovan Community Pneumonia Study Group Double blind randomized multicenter study in ambulatory community acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin abstr. LM-73 Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 378 American Society for Microbiology Washington D.C

10.1093/jac/36.2.385

White C. A. and R. G. Toothaker. 1985. Influence of ampicillin elimination half-life on in-vitro bactericidal effect. J. Antimicrob. Chemother. 15 (Suppl. A):257–260.

10.1093/jac/26.1.71

Wiedemann B. C. Rustige-Wiedemann and B. Kratz. 1995. Comparison of the pharmacodynamic properties of quinolones. Drugs 49 (Suppl. 2):269–271.

Wise R. D. Lister C. A. M. McNulty D. Griggs and J. M. Andrews. 1986. The comparative pharmacokinetics of five quinolones. J. Antimicrob. Chemother. 18 (Suppl. D):71–81.

10.1128/AAC.40.1.47

10.1128/AAC.37.11.2454

Thông tin
Thông tin xuất bản

Antimicrobial Agents and Chemotherapy

Tập 42 Số 11

2841-2847

Thông tin tác giả